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Background: In most cancer cases, the treatment 
choice for a pregnant patient is radiotherapy. In these 
patients, the abdomen is usually not exposed;           
therefore fetus exposure is due to peripheral dose 
(PD). The purpose of this study was to estimate the 
fetal dose (the maximum PD in each pregnancy 
stage) for modalities available and to fabricate and 
evaluate a generally applicable fetal shield. Materials 
and Methods: PD values were measured for brain, 
breast and mediastinum irradiation in a whole body 
anthropomorphic phantom using a NE 2571             
ionization chamber. An external shield was then           
designed to reduce the fetal dose to the standard 
dose limit, 5 mSv. Results: The range of PD values as 
a function of distance from the field’s edge were as 
follows 1) 9.4-259 cGy for Mantel field; 2) 6.5-95 cGy 
for chest wall irradiation with 10 MeV electrons, 3) 
8.5- 52.5 cGy for tangential field with Co-60 and 4) 
4.8-7.8 cGy for brain radiotherapy with 9 MV photon. 
PD values for the same setups using the fetal shield 
were as follows:  1) 1.4-22 cGy, 2) 0.5-4 cGy, 3) 1.5-5 
cGy and 4) under 1 cGy. Conclusions: The measured 
PD data sets can be used to estimate fetal dose for 
specific treatment setups and pregnancy stages. The 
use of external shield designed in this research           
reduced the fetal dose effectively to under the thresh-
old (a 70-90% reduction), except for the final stages 
of pregnancy in Hodgkin’s patients. Iran.	 J.	 Radiat.	
Res.,	2012;	10(3‐4):	151‐156 
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INTRODUCTION 
 
Radiotherapy plays a major role in the 
treatment of malignancies in pregnant           
patients. It is often one of the treatment  
modalities used as a sole treatment, or in 
combination with other modalities. The 
most common tumors of pregnant patients 
are lymphomas, leukemia, melanomas, and 
tumors located in the breast, uterine cervix 
and thyroid (1). In some cases it is not            
possible to postpone the radiation treatment 
until after delivery (2). Biological effects of 
ionizing radiation on the fetus include          
malformations, growth impairment, mental 
retardation, cancer induction, hereditary 
defects and death; therefore it is important 
to keep the dose to the fetus as low as             
possible. The frequency and magnitude of 
effects differ depending on the absorbed 
dose, type of radiation and the gestation age 
at which exposure occurs. As recommended 
by AAPM TG36, the equivalent absorbed 
dose received by a fetus should be kept           
under 5 mSv (1). Radiotherapy in pregnant 
patients is aimed towards controlling tumor 
growth while also giving the fetus the best 
chance for a normal life. To achieve the           
optimum balance between the risks and 
benefits of radiotherapy, the fetal dose has 
to be evaluated before treatment. 
The treatment volume in a pregnant          
patient should never contain the abdomen (1, 
3). Therefore, the dose absorbed outside of 
the radiation treatment field, also called the    
peripheral dose (PD), is responsible for fetal 
irradiation. The principal sources of PD are: 
(1) leakage radiation through the treatment 
head of the machine; (2) radiation scattered 
from the collimators and beam modifiers 
and (3) radiation scattered within the         
patient from the irradiated volume. For 
higher energy photon beams (>10 MV), the 
photo-neutron contribution to the absorbed 
dose becomes considerable and has to be 
taken into account (1). 
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PD depends on the following factors: (a) 
Distance from the radiation field edge: PD 
decreases almost exponentially with         
increasing distance from the field edge; (b) 
Depth in tissue or in phantom: PD             
dependence on depth is small; (c) Field size: 
PD increases with increasing field size; (d) 
The use of wedges and other beam             
modifiers: wedges increase the dose near the 
beam by a factor of 2 to 4 and the use of lead 
shielding devices can increase the PD by a 
factor of 2 to 5; (e) Beam energy: for a given 
depth and field size the PD for photons from 
4 to 25 MV is of the same order of                
magnitude and is qualitatively similar. In 
contrast, the PD from Co-60 at distances 
greater than 10 cm away from the field edge 
is considerably higher because of a larger 
amount of head leakage (1). Reduction in PD 
is achieved using gantry angle, field size 
and patient position adjustments. However, 
when treating a pregnant patient, the most 
effective method to reduce the fetal dose is 
through the use of shielding (1, 4). 
Fetal dose estimates in radiotherapy 
have been reported by many authors (1, 2, 4-
15). However, most of the information              
available on the measurement of fetal dose 
in radiotherapy has been reported for         
individual patients, specific treatment             
protocols and using phantoms specifically 
made for that patient. In a busy radiothera-
py department, however, individual patient 
dosimetry is a demanding option. The aim of 
the present study was to create a dataset for 
PD as a function of distance from the edge of 
the field for common treatment protocols 
and modalities available in our department. 
The PD dataset was then used to design and 
fabricate a generally applicable fetal shield.  
 
MATERIALS AND METHODS 
 
In this research, a generally applicable 
fetal shield is defined as a shield that is             
effective for all treatment protocols in order 
to protect the fetus in all stages of pregnan-
cy. Design of the fetal shield involved the 
following steps: (1) Simulate and implement 
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the treatment plan for common malignan-
cies in pregnant women in our center using 
physical phantoms, (2) measure unshielded 
fetal dose in the phantom, and (3)                 
implement a fetal shield and measure 
shielded fetal dose from the same treatment 
protocols.  
 
Treatment plans  
The malignancies considered were            
Hodgkin’s disease (HD) and Non Hodgkin 
Lymphoma (NHL), as well as breast and 
brain tumors for which the following            
radiotherapy protocols are commonly            
employed in our center: 
Plan A: HD and NHL treatment with        
mediastinum involvement using a Mantle 
field with 12 MV photon beams and a total 
dose of 3600 cGy. 
Plan B: Chest wall treatment, using a 10 
MeV electron beam and a total dose of 5000 
cGy.  
Plan C: Breast treatment, using two Co-60 
tangent beams and a total dose of 5000 cGy.  
Plan D: Brain treatment, using two 9 MV 
photon lateral beams and a total dose of 
6000 cGy.  
 
Measurement setup 
Treatment portals were delivered on a 
series of in-house acrylic phantoms which 
included the head and neck, chest and          
pelvis phantoms (figure 1). Phantoms were 
fabricated using acrylic sheets of 1 cm  
thickness. Measurements of peripheral dose 
were done in the abdomen and pelvis           
phantoms. The dosimeter was a 0.6 cm3 NE 
2571 ionization chamber (ND,W = 4.51 cGy/
nC). For measurements, a 2 cm thick slab of 
acrylic was used. A prefabricated hole of  
appropriate dimensions allowed the            
chamber to be inserted into this slab. The 
slab was then placed between the phantom 
slices at the measurement positions,           
specified by the distance from the portals 
inferior edge. PD does not depend strongly 
on depth and a depth of 10 cm has been           
recommended as a reference depth for fetal 
dose estimation (1, 4, 8, 10, 11, 14, 16).  
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Fetal shielding in radiotherapy  
Fetal dose was estimated by taking PD 
measurements at selected points away from 
the field’s inferior edge. Considering  the 
location of fetus in different stages of            
pregnancy period, these values  will reflect 
the range of dose throughout the fetus. In 
order to correlate the measurement points 
to the position of the fetus, a rate of 1 cm 
per week of pregnancy can be used for       
increase in the height of the fundus uteri 
with respect to the symphysis pubis (16, 17).  
energies result in similar photon energy 
spectra outside of the primary beam:  1- the 
parameters in the dose calculation protocol 
do not vary by more than a few percent over 
a wide range of photon energy, 2- the          
response of a thimble ion chamber is quite 
flat over this same energy range, and 3- an 
accuracy of 10% for a fetal dose estimate is 
acceptable (14). Therefore, in this work, the 
photon energy spectrum in the peripheral 
region of the 9 MV photon beam and 10 
MeV electron beam were defined by the  
central axis ionization ratio for the 9 MV 
beam. Also, since the measurement of PD 
involved very small magnitudes of dose, for 
each measurement, the number of MU was 
raised to 1000 and the readings were then 
normalized to the maximum dose along the 
central axis of the treatment field. 
 
Shielding design 
In this study a thickness of 4 cm of 
Cerrobend  (a Lipowitz's alloy containing 
50% bismuth, 26.7% Lead, 13.3% tin, and 
10% cadmium with a mass density of 9.6 g/
cm3 and a melting point of 70 °C) material 
(about 2 HVL) (19) for a nominal energy of 12 
MV was used to design a portable shield. 
Shield thickness and its material were            
selected based on the following data.            
According to the TG-36 report, regardless of 
energy, shielding thicknesses of 5 to 7 cm of 
lead or 6 to 8.5 cm of Cerrobend are           
adequate to reduce PD effectively (1).             
However, There are reports indicating that 
these thickness values seems to be too             
conservative for some treatment plans and 
some authors have reported using smaller 
thicknesses (1,4,10,11). Also, in a Monte Carlo 
evaluation of effective shielding of PD for 
different treatment plans (Mantel, head and 
neck and brain), it was shown that the dose 
reduction curve shows a plateau at a certain 
shield thicknesses (7). It was indicated that 
depending on the plan, there is an optimal 
thickness for which the head leakage and 
collimator scatter photons are effectively 
shielded and patient scatter becomes the 
main source of fetal dose. It was shown that 
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Figure 1. PD measurement set up for brain lateral fields in 
radiotherapy of the brain. 
PD determination 
Absorbed dose determination was           
performed according to the recommenda-
tions of IAEA’s TRS-398 protocol (18).              
Calculation of absorbed dose requires 
knowledge of the average energy of the pho-
ton spectrum at the point of measurement. 
The PD was measured at several points in 
the peripheral region of the fields, where 
the average energy of the photon spectrum 
cannot be measured accurately. Further-
more, the methodology for calculating          
absorbed dose is not clear, in the peripheral 
region of an electron field, where dose is         
deposited primarily by bremsstrahlung   
photons originated in the treatment head 
and phantom. 
Therefore, defining an average energy for 
the complex photon spectrum in the periph-
eral region of an electron beam is not 
straight forward. For the following reasons 
it was assumed that electron and photon 
beams with roughly equal nominal beam 
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when a 6 MV beam, was shielded with 3-9 
cm thickness of lead, the average dose           
reduction was about 2% per cm of shielding, 
i.e. additional shielding did not change the 
PD significantly. Therefore, since energy 
dependency of PD is negligible (1), one can 
conclude that for each treatment plan, an 
optimal shield thickness may be less than 
the thickness values recommended by TG36. 
It was also concluded that when the optimal 
number of HVL of lead and Cerrobend 
shielding was used, the shielding effects of 
the two materials were identical (7).   
The highest nominal energy used in this 
research was 12 MV. For high energy pho-
ton beams produced by clinical accelerators, 
several beam quality specifiers has been 
proposed in the literature (20, 21). These    
specifiers include: TPR20,10 (tissue phantom 
ratio at depths of 20 and 10 cm), PDD10 
(the percentage depth dose at 10 cm depth) 
and d80% (the depth at the 80% dose mark). 
In this research, d80% for the highest used 
energy photon beam (nominal energy of 12 
MV) was 85 mm. This depth corresponded to 
a 10 MV photon beam (21). Therefore, the 
highest photon energy used in this study 
was 10MV, for which photoneutron             
production was negligible (1).   
To support the shield independently from 
the couch, an iron table was positioned over 
the treatment couch. This table made            
treatment possible in different SSD’s. The 
vertical position of this table was made          
adjustable in 3 steps. To assemble the 
shield, Cerrobend sheets were placed on the 
table top, and also attached to the sides and 
front of the table. It is possible to wheel the 
iron table over the treatment coach as close 
as possible to the gantry without interfering 
with the treatment portals. The phantoms 
were then put into treatment position          
underneath the shield. In figures 2 the          
application of this shield in the treatment 
position is shown.  
 
Evaluation of abdominal shield 
The effectiveness of the designed shield 
was evaluated by repeating PD measure-
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ments while using the fabricated shield. For 
each treatment field, measurements were 
done in two distances, corresponding to the 
closest (point 1) and furthest (point 2) fetal 
positions relative to the beam edge.              
Peripheral dose at point 1 is the maximum 
dose that fetus receives at the end of third 
trimester. However, the dose at the second 
point reflects the dose that fetus receives in 
its most sensitive stage. PD for shielded 
fields at points 1 and 2 are compared to           
unshielded values for each plan.  
 
RESULTS  
 
The results of PD measurements for each 
treatment protocol at different distances are 
presented in figure 3. As reported in              
literature (1), PD values vary exponentially 
as a function of distance from the field’s 
edge. Maximum PD values correspond to 
the sub-diaphragm points closest to the                
inferior field edges, i.e. points at 1.5 cm           
distance from plans A and B, 3.5 cm from 
plan C and 35 cm distance from plan D. The 
ranges of PD values were as follows 1) 9.4-
259 cGy for plan A; 2) 6.5-95 cGy for plan B, 
3) 8.5- 52.5 cGy for plan C and 4) 4.8-7.8 
cGy for plan D.  
The effectiveness of the designed shield 
was evaluated by repeating PD measure-
ments using the fabricated shield. Shielded 
PD values measured at points 1 and 2, and 
Figure 2. Application of fetal shield in treatment of anterior 
field (lateral view). 
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Figure 3.  The results of PD measurements as a function of 
distance from the inferior edge of the field field’s edge during 
radiotherapy of plans A, B, C and D. PD values were normalized 
to central axis tumor dose. PD values vary exponentially as a 
function of distance from the field’s edge. 
Figure 4. Comparison PD values with (w) and without (w/o) a 
fetal shield in two sub-diaphragm positions, corresponding to 
the closest (point 1) and furthest fetal position (point 2) relative 
to the inferior beam edge. This shield reduces PD effectively in 
all plans but this thickness of material did not provide            
adequate protection of the fetus in final stages of pregnancy in 
plan A.   
Table 1. Evaluation of shield effectiveness in fetal dose reduction for Plans A, B, C and D. 
Fetal dose 
reduction   
percentage 
Percentage of fetal dose relative to the dose of 
field center 
Distance 
from inferior 
edge of the 
field (cm) 
Treatment 
plan 
Fetal dose with shield Fetal dose without shield 
75% 0.6% 2.5% 6 
A 
86% 0.04 0.28% 30 
71% 0.08% 0.28% 10 
B 
92% 0.01% 0.13% 33 
81% 0.1% 0.52% 10 
C 
82% 0.03% 0.17% 33 
91% 0.01% 0.11% 40 D 
<0.01% <0.01% 0.08% 64 
were compared to the unshielded values for 
each plan in figure 4. Similar results, but in 
term of percentage of tumor dose, are            
illustrated in table 1. These values show a 
fetal shield efficiency of 70-90 %.  
 
DISCUSSION 
 
A PD database was generated as a            
function of distance from the field edge for 
treatment protocols used to treat HD, breast 
and brain malignancies in our center. The              
generated PD dataset can be used to predict 
the range of fetal doses corresponding to the 
patient’s stage of pregnancy, for each             
treatment protocol. The range of PD values 
were as follows 1) 9.4-259 cGy for 12 MV 
Mantel fields; 2) 6.5-95 cGy for 10 MeV 
chest wall irradiation, 3) 8.5- 52.5 cGy for 
tangential breast field with Co-60 and 4) 4.8
-7.8 cGy for 9 MV brain radiotherapy. This 
research shows that the fetal dose for the 
evaluated treatment protocols was more 
than the standard limit of 5 cGy and it is 
therefore necessary to use an external 
shield when treating pregnant patients. 
Similar dose range values have been report-
ed by others (4, 5, 10, 13, 14, 22, 23). For example, 
Cygler et al. investigated the fetal dose in 
radiotherapy of a 23 weeks pregnant woman 
for HD with mantle field and 10 MV           
photons (5). The dose to the fundus and pubis 
were 10 and 3 cGy, in a 35 Gy total dose 
treatment. In another study, the fetal dose 
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was measured in a brain radiotherapy          
protocol using opposed 6 MeV lateral 10×15 
cm2 fields, both clinically and in phantom. 
Fetal dose was estimated to be 0.09% of the 
tumor dose (22). In another study, fetal dose 
in chest wall irradiation with electron beam 
was simulated using an anthropomorphic 
phantom and the measured dose to the           
unshielded fetus for this plan was 5.3 cGy 
(23). Implementation of the shield type           
described in this work reduced the peripher-
al dose effectively (70-90% reduction). The 
shield design in this work has purposely 
been made flexible so that it can be used 
with minimal modification in the irradiation 
of almost all treatment volumes. A             
thickness of 4 cm of Cerrobend was found to 
be very effective in reducing the fetal dose 
in a standard brain and breast and HD radi-
ation therapy course but this thickness of 
material did not provide adequate               
protection of the fetus in final stages of 
pregnancy in Hodgkin’s patients. For these 
patients, extra protection will be required.  
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